PedAM

Pediatric Disease Annotations & Medicines


	papilledema

Disease ID	520
Disease	papilledema
Definition	Swelling of the OPTIC DISK, usually in association with increased intracranial pressure, characterized by hyperemia, blurring of the disk margins, microhemorrhages, blind spot enlargement, and engorgement of retinal veins. Chronic papilledema may cause OPTIC ATROPHY and visual loss. (Miller et al., Clinical Neuro-Ophthalmology, 4th ed, p175)
Synonym	blurring of optic disc blurring of optic disk choked disc choked discs choked disk choked disks disc inflammation optic disk choked disk, choked disks, choked edema of optic disc edema of optic disc (disorder) edema, optic disk edema, optic papilla edemas, optic disk optic disc edema optic disc edema (disorder) optic disc oedema optic disc swelling optic disc swelling (finding) optic disc swollen optic discs blurred optic disk edema optic nerve papillitis optic papilla edema optic papillitis optic papillitis (disorder) papilledema (disorder) papilledema [disease/finding] papilledema nos papilledema nos (disorder) papilledema, nos papilledema, unspecified papillitis papillitis optic papillitis, optic papillitis, optic nerve papilloedema papilloedema (disorder) papilloedema nos swollen optic disc unspecified papilledema unspecified papilledema (disorder) unspecified papilloedema
DOID	DOID:146 DOID:10175
ICD10	ICD10CM:H47.10
UMLS	C0030353
MeSH	D010211
SNOMED-CT	SNOMEDCT_US_2016_09_01:248487006;SNOMEDCT_US_2016_09_01:73221001;SNOMEDCT_US_2016_09_01:423341008
Comorbidity	UMLS \| Disease \| Sentences' Count(Total Sentences:27) C0151740 \| intracranial hypertension \| 12 C0033845 \| idiopathic intracranial hypertension \| 11 C0020538 \| hypertension \| 9 C0029124 \| optic atrophy \| 5 C0151740 \| increased intracranial pressure \| 4 C0151740 \| raised intracranial pressure \| 4 C0033845 \| pseudotumor cerebri \| 3 C0010278 \| craniosynostosis \| 3 C0456909 \| vision loss \| 2 C0025289 \| meningitis \| 2 C0040128 \| thyroid diseases \| 1 C0029128 \| optic disc drusen \| 1 C0004134 \| ataxia \| 1 C0151620 \| hypertensive encephalopathy \| 1 C0085113 \| neurofibromatosis \| 1 C0029128 \| optic nerve head drusen \| 1 C0087086 \| thrombi \| 1 C0271355 \| lateral rectus palsy \| 1 C0028841 \| ocular hypotony \| 1 C0271051 \| macular edema \| 1 C0042790 \| visual disorder \| 1 C0431399 \| joubert syndrome \| 1 C0029089 \| ophthalmoplegia \| 1 C0040128 \| thyroid disease \| 1 C0036454 \| visual field loss \| 1 C0015464 \| facial palsy \| 1 C0020255 \| hydrocephalus \| 1
Curated Gene	(Waiting for update.)
Inferring Gene	(Waiting for update.)
Text Mined Gene	Entrez_id \| Symbol \| Score \| Resource(Total Genes:85) 920 \| CD4 \| DISEASES 6343 \| SCT \| DISEASES 27248 \| ERLEC1 \| DISEASES 2137 \| EXTL3 \| DISEASES 8797 \| TNFRSF10A \| DISEASES 8797 \| TNFRSF10A \| DISEASES 973 \| CD79A \| DISEASES 1594 \| CYP27B1 \| DISEASES 2026 \| ENO2 \| DISEASES 2670 \| GFAP \| DISEASES 1401 \| CRP \| DISEASES 1401 \| CRP \| DISEASES 3557 \| IL1RN \| DISEASES 8715 \| NOL4 \| DISEASES 9172 \| MYOM2 \| DISEASES 6855 \| SYP \| DISEASES 55717 \| WDR11 \| DISEASES 3931 \| LCAT \| DISEASES 5443 \| POMC \| DISEASES 8626 \| TP63 \| DISEASES 7157 \| TP53 \| DISEASES 5972 \| REN \| DISEASES 2041 \| EPHA1 \| DISEASES 5741 \| PTH \| DISEASES 163786 \| SASS6 \| DISEASES 673 \| BRAF \| DISEASES 56896 \| DPYSL5 \| DISEASES 1636 \| ACE \| DISEASES 4041 \| LRP5 \| DISEASES 115825 \| WDFY2 \| DISEASES 50964 \| SOST \| DISEASES 84168 \| ANTXR1 \| DISEASES 3479 \| IGF1 \| DISEASES 4968 \| OGG1 \| DISEASES 56246 \| MRAP \| DISEASES 2147 \| F2 \| DISEASES 1776 \| DNASE1L3 \| DISEASES 342898 \| SYCN \| DISEASES 3052 \| HCCS \| DISEASES 29933 \| GPR132 \| DISEASES 706 \| TSPO \| DISEASES 27445 \| PCLO \| DISEASES 5133 \| PDCD1 \| DISEASES 283 \| ANG \| DISEASES 114548 \| NLRP3 \| DISEASES 5549 \| PRELP \| DISEASES 5562 \| PRKAA1 \| DISEASES 3240 \| HP \| DISEASES 3177 \| SLC29A2 \| DISEASES 4763 \| NF1 \| DISEASES 9361 \| LONP1 \| DISEASES 6905 \| TBCE \| DISEASES 462 \| SERPINC1 \| DISEASES 103 \| ADAR \| DISEASES 8266 \| UBL4A \| DISEASES 2316 \| FLNA \| DISEASES 2334 \| AFF2 \| DISEASES 959 \| CD40LG \| DISEASES 959 \| CD40LG \| DISEASES 5730 \| PTGDS \| DISEASES 7422 \| VEGFA \| DISEASES 2516 \| NR5A1 \| DISEASES 3055 \| HCK \| DISEASES 4524 \| MTHFR \| DISEASES 1325 \| CORT \| DISEASES 2189 \| FANCG \| DISEASES 5251 \| PHEX \| DISEASES 3486 \| IGFBP3 \| DISEASES 4155 \| MBP \| DISEASES 9244 \| CRLF1 \| DISEASES 974 \| CD79B \| DISEASES 374654 \| KIF7 \| DISEASES 51520 \| LARS \| DISEASES 3119 \| HLA-DQB1 \| DISEASES 3778 \| KCNMA1 \| DISEASES 6295 \| SAG \| DISEASES 3550 \| IK \| DISEASES 6559 \| SLC12A3 \| DISEASES 84106 \| PRAM1 \| DISEASES 2263 \| FGFR2 \| DISEASES 374308 \| PTCHD3 \| DISEASES 51428 \| DDX41 \| DISEASES 100423062 \| IGLL5 \| DISEASES 8972 \| MGAM \| DISEASES 9301 \| SNORD27 \| DISEASES
Locus	(Waiting for update.)

Disease ID	520
Disease	papilledema
Integrated Phenotype	(Waiting for update.)
Text Mined Phenotype	HPO \| Name \| Sentences' Count(Total Phenotypes:31) HP:0002516 \| Intracranial pressure elevation \| 16 HP:0000822 \| Hypertension \| 9 HP:0000572 \| Visual loss \| 5 HP:0000648 \| Optic-nerve degeneration \| 5 HP:0001259 \| Coma \| 3 HP:0001363 \| Early fusion of cranial sutures \| 3 HP:0001287 \| Meningitis \| 2 HP:0000573 \| Retinal hemorrhage \| 2 HP:0007663 \| Central visual loss \| 2 HP:0002315 \| Headaches \| 2 HP:0010628 \| Facial palsy, unilateral or bilateral \| 1 HP:0030799 \| Scaphocephaly \| 1 HP:0040049 \| Macular edema \| 1 HP:0000820 \| Thyroid abnormality \| 1 HP:0002664 \| Neoplasia \| 1 HP:0000529 \| Slowly progressive visual loss \| 1 HP:0100774 \| Hyperostosis \| 1 HP:0011531 \| Hyalitis \| 1 HP:0011510 \| Drusen \| 1 HP:0001548 \| Overgrowth \| 1 HP:0002901 \| Hypocalcemia \| 1 HP:0001067 \| Neurofibromas \| 1 HP:0000505 \| Poor vision \| 1 HP:0012426 \| Optic disc drusen \| 1 HP:0001251 \| Ataxia \| 1 HP:0000602 \| Ophthalmoplegia \| 1 HP:0200057 \| relative afferent pupil defect \| 1 HP:0000238 \| Nonsyndromal hydrocephalus \| 1 HP:0001250 \| Seizures \| 1 HP:0001105 \| Retinal atrophy \| 1 HP:0001298 \| Encephalopathy \| 1

Disease ID	520
Disease	papilledema
Manually Symptom	UMLS \| Name(Total Manually Symptoms:12) C2364324 \| increased intracranial pressure C1740816 \| thoracic disc herniation C1282043 \| peripapillary choroidal neovascular membrane C0547030 \| visual disturbance C0344232 \| blurred vision C0271195 \| absolute scotoma C0238432 \| ependymoma of the spinal cord C0037930 \| spinal tumor C0037930 \| spinal cord tumors C0037930 \| spinal cord tumor C0036454 \| visual field defects C0027809 \| schwannoma
Text Mined Symptom	UMLS \| Name \| Sentences' Count(Total Symptoms:1) C0151740 \| increased intracranial pressure \| 4

Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)

All Snps(Total Genotypes:0)
(Waiting for update.)

GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)

GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)

Mapped by lexical matching(Total Items:0)
(Waiting for update.)

Mapped by homologous gene(Total Items:0)
(Waiting for update.)

Chemical(Total Drugs:10)
CUI	ChemicalName	ChemicalID	CasRN	DiseaseName	DiseaseID	DirectEvidence	PubMedIDs
C0030353	chloroquine	D002738	1954/5/7	papilledema	MESH:D010211	marker/mechanism	7120869
C0030353	doxycycline	D004318	564-25-0	papilledema	MESH:D010211	marker/mechanism	12649241
C0030353	medroxyprogesterone acetate	D017258	71-58-9	papilledema	MESH:D010211	marker/mechanism	2975585
C0030353	methotrexate	D008727	1959/5/2	papilledema	MESH:D010211	marker/mechanism	1568425
C0030353	omeprazole	D009853	73590-58-6	papilledema	MESH:D010211	marker/mechanism	9224084
C0030353	peginterferon alfa-2b	C417083	-	papilledema	MESH:D010211	marker/mechanism	15459850
C0030353	phenytoin	D010672	57-41-0	papilledema	MESH:D010211	marker/mechanism	3951721
C0030353	ribavirin	D012254	36791-04-5	papilledema	MESH:D010211	marker/mechanism	15459850
C0030353	tretinoin	D014212	302-79-4	papilledema	MESH:D010211	marker/mechanism	10466446
C0030353	vitamin a	D014801	11103-57-4	papilledema	MESH:D010211	marker/mechanism	151668

FDA approved drug and dosage information(Total Drugs:4)
DiseaseID	Drug_name	active_ingredients	strength	Dosage Form/Route	Marketing Status	TE code	RLD	RS
MESH:D010211	prilosec	omeprazole	20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	CAPSULE, DELAYED REL PELLETS;ORAL	Discontinued	None	Yes	No
MESH:D010211	prilosec	omeprazole	20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons	CAPSULE, DELAYED REL PELLETS;ORAL	Discontinued	None	Yes	No
MESH:D010211	omeprazole	omeprazole	20MG	TABLET, DELAYED RELEASE;ORAL	Over-the-counter	None	Yes	Yes
MESH:D010211	omeprazole	omeprazole	20MG	TABLET, DELAYED RELEASE;ORAL	Over-the-counter	None	Yes	Yes

FDA labeling changes(Total Drugs:4)
DiseaseID	Pediatric_Labeling_Date	Trade_Name	Generic_Name_or_Proper_Name	Indications Studied	Label Changes Summary	Product Labeling	BPCA(B)	PREA(P)	BPCA(B) and PREA(P)	Pediatric Rule (R)	Sponsor	Pediatric Exclusivity Granted Date	NNPS
MESH:D010211	12/7/2002	prilosec	omeprazole	Gastroesophageal reflux and erosive esophagitis	Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile	Labeling	B	-	-	-	AstraZeneca	-	FALSE'
MESH:D010211	03/20/2008	prilosec	omeprazole	Maintenance healing of erosive esophagitis	Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form	Labeling	-	-	B, P	-	AstraZeneca	1/5/2001	FALSE'
MESH:D010211	12/7/2002	prilosec	omeprazole	Gastroesophageal reflux and erosive esophagitis	Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile	Labeling	B	-	-	-	AstraZeneca	-	FALSE'
MESH:D010211	03/20/2008	prilosec	omeprazole	Maintenance healing of erosive esophagitis	Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form	Labeling	-	-	B, P	-	AstraZeneca	1/5/2001	FALSE'

Web
Analytics